These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37114703)

  • 1. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021.
    Stastna D; Drahota J; Lauer M; Mazouchova A; Menkyova I; Adamkova J; Ampapa R; Dufek M; Grunermelova M; Hradilek P; Kubala Havrdova E; Mares J; Martinkova A; Pavelek Z; Peterka M; Recmanova E; Rockova P; Stetkarova I; Stourac P; Vachova M; Horakova D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Apr; ():. PubMed ID: 37114703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.
    Horakova D; Rockova P; Jircikova J; Dolezal T; Vachova M; Hradilek P; Valis M; Sucha J; Martinkova A; Ampapa R; Grunermelova M; Stetkarova I; Stourac P; Mares J; Dufek M; Kmetova E; Adamkova J; Hrnciarova T
    Mult Scler Relat Disord; 2019 Oct; 35():196-202. PubMed ID: 31400559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
    Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
    Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is breastfeeding in MS harmful or not? An answer from real-world Czech data.
    Hradilek P; Zapletalova O; Hanulikova P; Havrdova EK; Woznicova I; Mazouchova A; Drahota J; Lauer M; Stetkarova I; Valis M; Libertinova J; Stourac P; Adamkova J; Ampapa R; Vachova M; Dufek M; Martinková A; Peterka M; Recmanova E; Mares J; Horakova D
    Mult Scler Relat Disord; 2023 Aug; 76():104790. PubMed ID: 37348317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.
    Leblanc S; Roux J; Tillaut H; Le Page E; Leray E
    Rev Neurol (Paris); 2021 Dec; 177(10):1250-1261. PubMed ID: 34253346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
    Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
    Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.
    Teni FS; Machado A; Murley C; He A; Fink K; Gyllensten H; Glaser A; Alexanderson K; Hillert J; Friberg E
    Mult Scler Relat Disord; 2023 Jan; 69():104456. PubMed ID: 36529068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.
    Braune S; Rossnagel F; Dikow H; Bergmann A;
    BMJ Open; 2021 Aug; 11(8):e042480. PubMed ID: 34344670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 16. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    Filippi M; Amato MP; Centonze D; Gallo P; Gasperini C; Inglese M; Patti F; Pozzilli C; Preziosa P; Trojano M
    J Neurol; 2022 Oct; 269(10):5382-5394. PubMed ID: 35608658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.
    Vollmer BL; Wolf AB; Sillau S; Corboy JR; Alvarez E
    Front Neurol; 2021; 12():799138. PubMed ID: 35145470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
    Seifer G; Arun T; Capela C; Laureys G; Jones E; Dominguez-Castro P; Sanchez-de la Rosa R; Hiltl S; Iaffaldano P
    Mult Scler Relat Disord; 2023 Aug; 76():104770. PubMed ID: 37307690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study.
    Moccia M; Affinito G; Marrazzo G; Ciarambino T; Di Procolo P; Confalonieri L; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    Neurol Int; 2024 Mar; 16(2):394-405. PubMed ID: 38668126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach.
    Ghezzi A
    Neurol Ther; 2024 Aug; 13(4):949-963. PubMed ID: 38822947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.